Clinical monitoring GLP-1 therapy requires medical supervision, dose adjustment, and monitoring for adverse effects

Who is Retatrutide 40 mg for Retatrutide is an investigational drug (Phase 3), not yet approved by the FDA/EMA Triple GLP-1 / GIP / glucagon agonist a unique mechanism of action For patients for whom single (Ozempic) or dual (Mounjaro) agonists did not deliver enough effect Strictly under medical supervision Retatrutide 40 mg compared to other doses Retatrutide 12 mg showed ~24% weight loss over 48 weeks (Phase 2, NEJM 2023) Compared to Mounjaro 15 mg (~2226%) a similar effect, but with a triple mechanism Key difference: retatrutide activates the glucagon receptor, increasing energy expenditure No final Phase 3 results yet efficacy and safety are still being confirmed FAQ about Retatrutide 40 mg (ALLUVI) 1 ALLUVI Retatrutide injection pen (40 mg total, dial mechanism up to 10 mg per dose), 12 single-use ALLUVI needles and dosing instructions (Dosage Guide) with step-by-step schedule from 2.5 mg to 10 mg

Similarly, discussing expected side effects prepares patients for the initial adjustment period
This category is designed for researchers studying the biological systems connected to sexual health, hormonal regulation, reproductive support, and overall physiological balance